179 related articles for article (PubMed ID: 25196952)
1. Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling.
Kolluru GK; Majumder S; Chatterjee S
Nitric Oxide; 2014 Dec; 43():45-54. PubMed ID: 25196952
[TBL] [Abstract][Full Text] [Related]
2. Signaling through Rho GTPase pathway as viable drug target.
Lu Q; Longo FM; Zhou H; Massa SM; Chen YH
Curr Med Chem; 2009; 16(11):1355-65. PubMed ID: 19355891
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Microglial Phagocytosis by RhoA/ROCK-Inhibiting Drugs.
Scheiblich H; Bicker G
Cell Mol Neurobiol; 2017 Apr; 37(3):461-473. PubMed ID: 27178562
[TBL] [Abstract][Full Text] [Related]
4. ρ-Kinase inhibition reduces early microvascular leukocyte accumulation in the rat kidney following ischemia-reperfusion injury: roles of nitric oxide and blood flow.
Versteilen AM; Blaauw N; Di Maggio F; Groeneveld AB; Sipkema P; Musters RJ; Tangelder GJ
Nephron Exp Nephrol; 2011; 118(4):e79-86. PubMed ID: 21311198
[TBL] [Abstract][Full Text] [Related]
5. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
Kitamura K; Tada S; Nakamoto N; Toda K; Horikawa H; Kurita S; Tsunematsu S; Kumagai N; Ishii H; Saito H; Hibi T
J Gastroenterol Hepatol; 2007 Nov; 22(11):2022-33. PubMed ID: 17914985
[TBL] [Abstract][Full Text] [Related]
6. 28-Day hindlimb unweighting reduces expression of Rho kinase and inhibits its effects in femoral artery of rat.
Wang ZC; Liu H; Bai YG; Yu JW; Zhang HJ; Cheng YP; Bao JX; Ren XL; Ma HZ; Ma J
J Physiol Biochem; 2015 Jun; 71(2):205-16. PubMed ID: 25761652
[TBL] [Abstract][Full Text] [Related]
7. Promotion of mouse embryonic stem cell differentiation by Rho kinase inhibitor Y-27632.
Kamishibahara Y; Kawaguchi H; Shimizu N
Neurosci Lett; 2014 Sep; 579():58-63. PubMed ID: 25038419
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide inhibits endothelin-1-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway.
Hunter JC; Zeidan A; Javadov S; Kilić A; Rajapurohitam V; Karmazyn M
J Mol Cell Cardiol; 2009 Dec; 47(6):810-8. PubMed ID: 19799911
[TBL] [Abstract][Full Text] [Related]
9. Y-27632, a Rho-associated protein kinase inhibitor, inhibits systemic lupus erythematosus.
Wang Y; Lu Y; Chai J; Sun M; Hu X; He W; Ge M; Xie C
Biomed Pharmacother; 2017 Apr; 88():359-366. PubMed ID: 28122300
[TBL] [Abstract][Full Text] [Related]
10. RhoA/Rho-Kinase in the Cardiovascular System.
Shimokawa H; Sunamura S; Satoh K
Circ Res; 2016 Jan; 118(2):352-66. PubMed ID: 26838319
[TBL] [Abstract][Full Text] [Related]
11. The role of Rho-associated kinase in differential regulation by statins of interleukin-1beta- and lipopolysaccharide-mediated nuclear factor kappaB activation and inducible nitric-oxide synthase gene expression in vascular smooth muscle cells.
Wei CY; Huang KC; Chou YH; Hsieh PF; Lin KH; Lin WW
Mol Pharmacol; 2006 Mar; 69(3):960-7. PubMed ID: 16317111
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth.
Routhier A; Astuccio M; Lahey D; Monfredo N; Johnson A; Callahan W; Partington A; Fellows K; Ouellette L; Zhidro S; Goodrow C; Smith A; Sullivan K; Simone P; Le L; Vezuli B; Zohni M; West E; Gleason D; Bryan B
Oncol Rep; 2010 Mar; 23(3):861-7. PubMed ID: 20127030
[TBL] [Abstract][Full Text] [Related]
13. Rho-kinase activation contributes to Lps-induced impairment of endothelial nitric oxide synthase activation by endothelin-1 in cultured hepatic sinusoidal endothelial cells.
Kwok W; Clemens MG
Shock; 2014 Dec; 42(6):554-61. PubMed ID: 25243430
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Rho-ROCK signaling induces apoptotic and non-apoptotic PS exposure in cardiomyocytes via inhibition of flippase.
Krijnen PA; Sipkens JA; Molling JW; Rauwerda JA; Stehouwer CD; Muller A; Paulus WJ; van Nieuw Amerongen GP; Hack CE; Verhoeven AJ; van Hinsbergh VW; Niessen HW
J Mol Cell Cardiol; 2010 Nov; 49(5):781-90. PubMed ID: 20691698
[TBL] [Abstract][Full Text] [Related]
15. [Advances in the study of Rho kinase and its inhibitors].
Duan WG; Yuan ST; Liao H; Yan M; Zhang LY
Yao Xue Xue Bao; 2007 Oct; 42(10):1013-22. PubMed ID: 18229604
[TBL] [Abstract][Full Text] [Related]
16. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
Zhou H; Li YJ
Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664
[TBL] [Abstract][Full Text] [Related]
17. The effect of Rho-associated kinase inhibition on the proteome pattern of dissociated human embryonic stem cells.
Gharechahi J; Pakzad M; Mirshavaladi S; Sharifitabar M; Baharvand H; Salekdeh GH
Mol Biosyst; 2014 Mar; 10(3):640-52. PubMed ID: 24430196
[TBL] [Abstract][Full Text] [Related]
18. Epithelial inducible nitric oxide synthase causes bacterial translocation by impairment of enterocytic tight junctions via intracellular signals of Rho-associated kinase and protein kinase C zeta.
Wu LL; Chiu HD; Peng WH; Lin BR; Lu KS; Lu YZ; Yu LC
Crit Care Med; 2011 Sep; 39(9):2087-98. PubMed ID: 21552122
[TBL] [Abstract][Full Text] [Related]
19. Rho kinase as a therapeutic target in cardiovascular disease.
Surma M; Wei L; Shi J
Future Cardiol; 2011 Sep; 7(5):657-71. PubMed ID: 21929346
[TBL] [Abstract][Full Text] [Related]
20. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation.
Zohrabian VM; Forzani B; Chau Z; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2009 Jan; 29(1):119-23. PubMed ID: 19331140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
